Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The first wave of shipments includes several countries, such as Germany, France and Austria
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Subscribe To Our Newsletter & Stay Updated
